Dosing & Uses
Dosage Forms & Strengths
- 200mg/20mL (10mg/mL)
Indicated for treatment of acute uncomplicated influenza in patients aged &ge:18 yr who have been symptomatic for no more than 2 days
600 mg IV as a single dose
Infuse diluted IV over 15-30 minutes
- CrCl 30-49 mL/min: 200 mg IV as a single dose
- CrCl 10-29 mL/min: 100 mg IV as a single dose
Limitations of use
- Efficacy based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus; a limited number of subjects infected with influenza B virus were enrolled
- Influenza viruses change over time and emergence of resistance substitutions could decrease drug effectiveness
- Efficacy could not be established in patients with serious influenza requiring hospitalization
<18 years: Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Neutrophils <1 x 10^9/L (8%)
Increased serum glucose (>160 mg/dL) (5%)
Creatine phosphokinase (≥6 xULN) (5%)
AST and ALT increased (3%)
Dermatologic: Stevens-Johnson syndrome, exfoliative dermatitis, rash
General disorders and administration site conditions: anaphylactic/anaphylactoid reactions
Psychiatric: abnormal behavior, hallucination
Known serious hypersensitivity or anaphylaxis to peramivir or any component of the product; severe allergic reactions have included anaphylaxis, erythema multiforme, and Stevens-Johnson Syndrome
Serious skin reactions reported including erythema multiforme and Stevens-Johnson syndrome; discontinue and initiate appropriate treatment (see Contraindications)
Influenza can be associated with neurologic and behavioral symptoms including hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes
Pregnancy & Lactation
Pregnancy category C; No data available for use during pregnancy
Lactation: unknown whether distributed in breast milk, do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Elicits antiviral activity by inhibiting influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells
Dextrose 5% in water
Lactated Ringer solution
Contains no preservatives or bacteriostatic agents; do not use if seal over vial opening is broken or missing
Inspect vial for particulate matter and discoloration
Dilute appropriate dose in 0.9% or 0.45% NaCl, D5W, or lactated Ringer solution to a maximum volume of 100 mL
Administer IV over 15-30 minutes
Unopened vials: Store in original cartons at 20-25°C (68-77°F); excursions are permitted to 15-30°C (59-86°F)
Diluted solution: Administer immediately or store refrigerated (2-8°C [36-46°F]) for up to 24 hr
If refrigerated, allow the diluted solution to reach room temperature then administer immediately
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.